Earnings ·
BlossomHill Therapeutics reported second quarter 2026 financial results on September 18, 2026
BLSMBlossomHill Therapeutics, Inc.
BlossomHill Therapeutics reported second quarter 2026 financial results on September 18, 2026. The company posted a net loss of $23.8 million, or $(8.75) per share, compared to a $13.2 million loss in the prior year period. Research and development expenses increased to $21.4 million from $12.5 million, driven by clinical trial costs for BH-30643 and IND-enabling studies for BH-501284. General and administrative expenses rose to $3.3 million from $1.6 million. Cash and cash equivalents totaled $95.4 million as of June 30, 2026. The company also announced the completion of an upsized initial public offering in August 2026, generating approximately $168.3 million in gross proceeds from the sale of 10,516,240 shares. Additionally, BlossomHill received FDA Fast Track designation for BH-30643 to treat advanced EGFR C797S-positive non-small cell lung cancer and expanded its board with two new appointments. BlossomHill Therapeutics is a clinical-stage biopharmaceutical company developing small molecule medicines for cancer treatment.